C4 Therapeutics price target lowered to $17 from $25 at H.C. Wainwright

H.C. Wainwright analyst Andrew Fein lowered the firm’s price target on C4 Therapeutics to $17 from $25 and keeps a Buy rating on the shares. The analyst expects the stock to be rangebound toward its 52-week low until CFT7455 safety profile is deemed a “non-liability to the program.”